⁍ The vaccine triggers protective antibodies and T-cells in older age groups, the FT said.
⁍ Details of the finding are expected to be published shortly in a clinical journal.
⁍ AstraZeneca is seen as a frontrunner in the race to produce a vaccine to protect against COVID-19.
– An experimental vaccine being developed by AstraZeneca and the University of Oxford appears to be effective in protecting seniors against the common cold, the Financial Times reports. The vaccine, which is being tested on healthy adults aged 18 to 55, triggers the body’s immune system to produce antibodies and T-cells that protect seniors against the common cold-like virus known as coronavirus, or COVID-19. Researchers are seeking evidence that the vaccine will be effective against COVID-19, which kills hundreds of people each year, most of them in their 70s and 80s, Reuters reports.
Source: https://www.reuters.com/article/us-health-coronavirus-astrazeneca-vaccin/oxford-covid-19-vaccine-trials-produce-robust-immune-response-in-elderly-ft-idUSKBN27B0IV